🧠 Stress awareness tip: There is much evidence that yoga, tai chi and qigong are effective practices in reducing stress levels. 🧘🏻‍♀️ Much of the research emphasizes the mind-body connection and the meditative aspects of these activities, linking movement to breath and mindfulness. Other benefits of these practices on stress reduction include—

🌿 Better ability to adapt to stressors
🌿 Increased feelings of confidence, self-esteem and awareness of self
🌿 Increased musculoskeletal activation and awareness

Reset Tip: What is the one common thing shared between all patients suffering from chronic pain?

Dr. Adam Klotzek discusses the commonalities in the brain and nervous system amongst those suffering from pain.

#chronicpain #carrickinstitute #carricktrained #carrickinsight #painreset #reset #neuroscience #clinicalneurology

Transcription:

– In today’s video, we’re gonna talk about the one common thing, neurologically, that is seen occurring in people’s brains who are experiencing chronic pain. So one of the things that we are learning with regards to chronic pain, or a common feature that is seen in individual’s brains who are experiencing chronic pain, is basically the following: we are noticing that there is a common area of the brain that gets activated in anyone who is experiencing pain, and that area is called your anterior cingulate. Now, what’s interesting about the anterior cingulate it’s not only that it’s activated in everyone who’s experiencing pain, but it’s also activated when people experience the threat of something being painful. So if I was told that if I move my shoulder a certain way and that’s going to damage my shoulder or hurt me more, that, in fact, is threatening to me, and thus I’m gonna see activation of the anterior cingulate. So we see it associated with threat, we see it associated with pain, and the other thing that’s really, really cool about the anterior cingulate it’s that one of its main purposes is to correct for errors. So we see error correction. So what that means for a clinician is that, if you have error in a movement, then your anterior cingulate is going to be activated in order to try to correct for that error. Now, the error in movement can be deemed as a threat to us, to the organism, and therefore, as being a threat, it can also give you the experience of pain. At the Carrick Institute’s Pain Reset Neurology Series, we’d leverage this idea of the anterior cingulate being involved in error correction, being involved in the generation of pain, and also being activated when there is a perceived threat, i.e. in a movement that is not occurring properly, to help get our chronic patients out of pain that is more effective and longer-lasting than other types of applications. If you wanna learn more, please contact the Carrick Institute or visit our website. Thank you.

The date of the International Symposium has been postponed to February 3-5th, 2017

Hello. I am Ted Carrick and I would like to extend a personal invitation to you to attend the International Symposium on Clinical Neuroscience held in Orlando Florida this February 3-5th 2017.

The Symposium is a brilliant one with delegates already registered coming from all corners of the world. The faculty that will be presenting the research hail from the most prestigious of universities and are well known not only in the literature for the books they have writing and the articles they have published but for their clinical acumen. It will be an exciting evidenced based, fast-paced symposium that reflects the top of the top of knowledge in the neurosciences as well as the knowledge presented there is also going to be a very robust poster presentation to accompany that platform presentation and all sorts of social activities that really will make you very, very satisfied and pleased that you registered to attend.

I think that is the meeting of the year. I’m going to be there and I hope to see you there as well.

To learn more and register, visit the ISCN 2017 website.

International Symposium on Clinical Neuroscience
Optimization of Human Function
October 7-9, 2016
Wyndham Orlando Resort International Drive
8001 International Drive Orlando, FL 32819

The submission deadline has been extended to Friday, August 31, 2016. Please visit the Frontiers Neurology website for more info and to make a submission. All Poster Presentations will be subject to peer review and if accepted will be published in the PubMed indexed Journal Frontiers Neurology.

We are proud to announce the addition of DimaAbdelmannan to our speaker list for this years ISCN.

Dr. Dima Abdelmannan is Professor of Medicine and Dean of Clinical Medicine at the Dubai Medical College in Dubai. U.A.E . She is also a Consultant Endocrinologist at the Dubai Diabetes Center at Dubai Health Authority. Dr. Abdelmannan completed her post-graduate education in the UK then the USA . In the USA, She completed her internal medicine training at Cleveland Clinic Health System and then completed fellowship training in Endocrinology, Diabetes and Metabolism at Case Western Reserve University, in Cleveland, OH. Dr. Abdelmannan continued to do clinical and research work at the same institution for several years before returning to Dubai, UAE.  Her research work is in the field of Pituitary and Adrenal diseases as well as Diabetes.  Dr. Abdelmannan has been interested in Medical Education besides clinical endocrinology and research, and therefore accepted a faculty position at the medical school in Dubai in order to contribute to improving the standards of medical education globally. Dr. Abdelmannan is a clinical scholar at Harvard Medical School and is also a scholar of the Harvard Macy Institute where she is actively involved in implementing efficient ways in medical pedagogy including simulation and e-learning.

Her presentation is an exciting look at her research and clinical applications specific to Type 2 Diabetes.  She will explore her research involving the identification of risk factors for this disorder and provide insights into further diagnosis and treatment using a nonpharmacologic approach.  Her presentation is in 2 parts as follows:

Nonpharmacologic Treatment for Type 2 Diabetes –
Type 2 Diabetes Mellitus (T2DM) encompasses two key pathophysiologic defects: increased insulin resistance and relative or absolute insulin secretory deficiency. Focusing on these two abnormalities to normalize glucose levels in someone with T2DM, one must either decrease insulin resistance or increase the amount of available insulin to compensate for a given degree of insulin resistance. Non-pharmacological treatments have been proven effective in the treatment of T2DM.

The major components of non-pharmacologic therapy of blood glucose in type 2 diabetes are dietary modification , exercise and weight reduction. Dietary modification is the process by which the dietary plan is tailored for people with diabetes, based on medical, lifestyle, and personal factors. It is an integral component of diabetes management and diabetes self-management education. Weight reduction for patients with type 2 diabetes who are overweight (BMI ≥25 to 29.9) and obese (BMI ≥30), major emphasis should be placed on lowering caloric intake, increasing physical activity, and behavior modification to achieve weight loss. Exercise and muscle metabolism: As in normal individuals, exercise has both short (e.g. Improves insulin sensitivity) and long-term (e.g. improving exercise capacity) effects on carbohydrate metabolism in diabetic patients as it does in nondiabetics.

Can we identify people at risk for T2DM earlier using a single dose of Dexamethasone? –
Type 2 Diabetes (T2DM) is an on-going process that develops over the span of many years. Several risk factors are known to predispose non-diabetic individuals to diabetes. Family history and obesity are the best predictors among the other known risk factors (diet, life style, impaired glucose tolerance (IGT), impaired fasting glycemia (IFG), etc.). Yet, not all subjects with the mentioned risk factors become diabetic. Because the genetic predisposition to T2DM causes impaired insulin secretory response to insulin resistance, it follows that, induction of insulin resistance in an insulin sensitive individual and monitoring the beta cell response to this insulin resistance will unveil the genetic predisposition of T2DM. Dexamethasone (DEX), a glucocorticoid, causes insulin resistance in skeletal muscle and liver and results in increased rate of hepatic glucose production. We characterized the dynamic changes in plasma glucose and insulin concentration in normal glucose tolerant individuals in response to acute exposure to DEX. We have demonstrated that normal glucose tolerant individuals manifest a dose response increase in insulin secretion during the OGTT 24 hours following DEX administration. Looking at a high-risk non-diabetic patient ( e.g. offspring of two diabetic parents), insulin resistance caused by single DEX administration, similar to that caused by elevation of plasma FFA concentration, will result in a decrease in insulin secretion and beta cell function. The results of these studies will demonstrate that “metabolic stress by single DEX administration” produces a differential response in insulin secretion that will distinguish between subjects who are genetically predisposed to develop T2DM and subjects without genetic predisposition to T2DM, and therefore, the former group is at an increased risk of future T2DM. Early identification of people who will develop type 2 DM through a cost-effective test that can be potentially applied to the community is the main potential significance of this study.

Hi! It’s exciting now to be involved in clinical neuroscience. I just want to give you an update on the symposium on clinical neuroscience. This year it is going to be in Orlando, FL again. The topic for this year’s theme is clinical neuroscience of optimization of human function.

If you were here last here, you saw hundreds of people from around the world along with top people from top institutions. The same thing is happening this year but with new instructors and faculty, robust abstracts and poster presentations.

There is also a call for abstracts. The abstracts are to be themed in regards to clinical case studies. So if you have a case that is meaningful, we will help you write it up so you can publish it and then present it at the symposium.

The conference is in Orlando, and it is priced pretty fairly now with some amazing room rates at some glorious resorts in the area. You will be seeing people from Cambridge, Harvard, Yale, and Paris. Some really big names and heads of departments and researchers whose books and papers you have certainly read.

I am excited to be involved with this again. I think it is really going to be tops! If you are interested in increasing human function, then this really is the symposium for you this year.

So how does this work? We are to be talking about how does one increase human function after someone’s had cancer. How does one improve human function after radiculopathy or back pain? How does one increase human function after dystonia? How does one enhance human function after stroke? We have world class people that are going give you the gamut of individual conditions and then direct you towards a treatment that is largely without the use of drugs or surgery. It is right in the wheelhouse of most of house.

It is going to be exciting. Look for it with some future announcements and in the ISCN2016 website so you can read about the individual speakers so you can see what they are going to be sharing.

It has been pretty exciting to be involved in this journey from the very beginning when there wasn’t any functional neurology. I’m just excited the world is turning as its getting better and better for us every year.

Plan to be in Orlando, FL in October. It is a major event of the year for us and I’m happy to be part of it. Take good care!

In health,

Prof. Ted Carrick, DC, Ph.D